Zobrazeno 1 - 10
of 40
pro vyhledávání: '"John, Whitesides"'
Autor:
Kwan-Ki Hwang, Ashley M Trama, Daniel M Kozink, Xi Chen, Kevin Wiehe, Abby J Cooper, Shi-Mao Xia, Minyue Wang, Dawn J Marshall, John Whitesides, Munir Alam, Georgia D Tomaras, Steven L Allen, Kanti R Rai, Jane McKeating, Rosa Catera, Xiao-Jie Yan, Charles C Chu, Garnett Kelsoe, Hua-Xin Liao, Nicholas Chiorazzi, Barton F Haynes
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e90725 (2014)
B-cell chronic lymphocytic leukemia (B-CLL) patients expressing unmutated immunoglobulin heavy variable regions (IGHVs) use the IGHV1-69 B cell receptor (BCR) in 25% of cases. Since HIV-1 envelope gp41 antibodies also frequently use IGHV1-69 gene seg
Externí odkaz:
https://doaj.org/article/ca7014c87aff4e82ac23ca58b421f885
Autor:
Anyzeila Diaz, Vincent Badalamenti, Teresa Gasalla, John Whitesides, Stephan Arnold, Cindy McShea, Toufic Fakhoury
Publikováno v:
Epilepsy Research. 141:73-82
Brivaracetam (BRV), a selective, high-affinity ligand for synaptic vesicle protein 2A, is a new antiepileptic drug (AED) approved for monotherapy (in the USA) and adjunctive treatment of focal (partial-onset) seizures in adults, at a dose range of 50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::922f69034574ac5da0b3a39406a8c20d
https://doi.org/10.1016/j.eplepsyres.2018.02.005
https://doi.org/10.1016/j.eplepsyres.2018.02.005
Publikováno v:
Clinical Pharmacology : Advances and Applications
Brivaracetam (BRV; Briviact) is a new antiepileptic drug (AED) approved for adjunctive treatment of focal (partial-onset) seizures in adults. BRV is a selective, high-affinity ligand for synaptic vesicle 2A (SV2A) with 15- to 30-fold higher affinity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db4bba57764a546b3028def34d3e2f50
https://doi.org/10.2147/cpaa.s114072
https://doi.org/10.2147/cpaa.s114072
Autor:
Lynn Morris, Xi Chen, Munir Alam, Georgia Tomaras, Ruijun Zhang, Dawn J Marshall, Bing Chen, Robert Parks, Andrew Foulger, Frederick Jaeger, Michele Donathan, Mira Bilska, Elin S Gray, Salim S Abdool Karim, Thomas B Kepler, John Whitesides, David Montefiori, M Anthony Moody, Hua-Xin Liao, Barton F Haynes
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e23532 (2011)
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by experimental HIV-1 vaccines. When these antibodies do occur, it is important to be able to isolate and characterize them to provide clues for vaccine desig
Externí odkaz:
https://doaj.org/article/9d5bc32a5f504e11ae3e54e27a1dc13c
Autor:
Rebecca Beale, John Whitesides, Jennifer S. Evans, Manuel Toledo, Sara Steeves, Sami Elmoufti, Simon Borghs, Rebecca Townsend
Publikováno v:
Epilepsy Research. 138:53-61
Antiepileptic drug (AED) retention rates are frequently reported in the literature and used to inform clinical decision-making, but methodological differences in the determination of retention rates make comparisons between trials difficult. Open-lab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9985e41a20e4590ee2ab455a1599cc86
https://doi.org/10.1016/j.eplepsyres.2017.10.008
https://doi.org/10.1016/j.eplepsyres.2017.10.008
Autor:
Sami Elmoufti, Pavel Klein, Ali A. Asadi-Pooya, Anyzeila Diaz, Jimmy Schiemann, John Whitesides, Steve Chung, Michael R. Sperling
Publikováno v:
Epilepsy Research. 131:70-75
Brivaracetam (BRV), a selective, high-affinity ligand for synaptic vesicle protein 2A, is a new antiepileptic drug (AED) for adjunctive treatment of focal (partial-onset) seizures in adults with epilepsy. This post-hoc analysis was conducted to explo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86f0a688fd7d671698f90170b5aa09f6
Publikováno v:
Epilepsy & Behavior. 103:106864
Objective The objective of this analysis was to provide a comprehensive analysis of safety data for adjunctive brivaracetam (BRV), an antiepileptic drug (AED) of the racetam class, for treatment of focal seizures in patients with epilepsy. Methods Da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3759dd4478854db22fc6931a8cf99dd2
https://doi.org/10.1016/j.yebeh.2019.106864
https://doi.org/10.1016/j.yebeh.2019.106864
Autor:
Michael R. Sperling, Pavel Klein, John Whitesides, Jimmy Schiemann, Patrick Kwan, Tracy Stalvey, Wei Liang, Christian Brandt
Publikováno v:
Epilepsia. 56:1890-1898
SummaryObjective Brivaracetam (BRV), a selective and high-affinity synaptic vesicle protein 2A ligand, is in development as adjunctive treatment for partial-onset (focal) seizures (POS). This phase 3 study (N01358; NCT01261325) aimed to confirm the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ad07cc36306e38deccb2376f016c4c9
https://doi.org/10.1111/epi.13212
https://doi.org/10.1111/epi.13212
Autor:
Jimmy Schiemann, John Whitesides, Pavel Klein, Anyzeila Diaz, Selim R. Benbadis, Sami Elmoufti
Publikováno v:
Epilepsybehavior : EB. 80
Objective The objective was to assess the efficacy and safety of adjunctive brivaracetam (BRV) with concomitant use of lamotrigine (LTG) or topiramate (TPM) in patients with uncontrolled focal seizures. Methods Data were pooled from three randomized,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04decdf074e7d1f5c094900a2ffa59b5
https://pubmed.ncbi.nlm.nih.gov/29414542
https://pubmed.ncbi.nlm.nih.gov/29414542
Publikováno v:
Epilepsia. 58(2)
Time to onset of sustained ≥50% responder status (SRS) was assessed for the pooled patient population receiving brivaracetam (BRV) 50, 100, or 200 mg/day or placebo in three randomized phase III studies (NCT00464269, NCT00490035, and NCT01261325).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38037f8d203a507f0dbf5c248a0d2890
https://pubmed.ncbi.nlm.nih.gov/27988967
https://pubmed.ncbi.nlm.nih.gov/27988967